Transgenomic, a global biotechnology company, and US-based PerkinElmer have entered into a collaboration agreement for marketing and distributing Transgenomic’s line of molecular diagnostic oncology products in territories outside the US.
Pursuant to the terms of agreement, PerkinElmer will have the non-exclusive right to begin sales, marketing, distribution and field service activities globally (excluding US) for Transgenomic’s oncology diagnostic test portfolio of products that include CRC RAScan and ACE kits, for use on the PerkinElmer LabChip MultiDx platform.
The agreement is with effect from January 1, 2014.
Transgenomic CEO Paul Kinnon noted PerkinElmer is a leading global life science company with a strong reach throughout the clinical diagnostics market.
"They are the ideal commercial collaborator for our oncology genetic testing portfolio outside of the US. This portfolio addresses a growing breadth of genetic markers important to assessing risk, prognosis and treatment of a variety of cancers," Kinnon added.
The CE Mark approved CRC RAScan mutation detection test has been designed to screen selected KRAS and NRAS mutations (collectively RAS mutations) in metastatic colorectal cancer (mCRC) patients.
This test can screen RAS mutations at very low levels that cannot be detected using traditional Sanger Sequencing methods.
Initial launch of the product will be in Europe and financial terms of the agreement were not disclosed.